Current therapeutics employed in diabetes are now being tested for their potential effects in preserving beta-cell survival, given that maintaining endogenous insulin secretion—even to a minor degree—may improve clinical outcomes in diabetic patients10,11. Here, INS is linked to diabetes mellitus.